Press Releases
Filter By Year
November
-
November 09, 2019
New Data on Filgotinib in Rheumatoid Arthritis (RA) Demonstrate Durable Efficacy and Safety Profile -
November 08, 2019
Data Showing Potential for Machine Learning to Advance Understanding of Nonalcoholic Steatohepatitis (NASH) Presented at the Liver Meeting® 2019 -
November 08, 2019
Gilead Announces New Data from Viral Hepatitis Research Programs at The Liver Meeting® 2019 -
November 08, 2019
Gilead Presents Data on Investigational HIV-1 Capsid Inhibitor GS-6207 as a Potential Component of Long-Acting HIV Therapy -
November 06, 2019
Kite to Present New Data From Industry-leading Cell Therapy Portfolio at ASH 2019 -
November 06, 2019
Gilead Presents 96-week Discover Trial Data Supporting Non-inferior Efficacy and Key Safety Differences of Descovy For PrEP™ Compared With Truvada For PrEP® -
November 06, 2019
Gilead’s Biktarvy Maintained High Efficacy With No Cases of Treatment-Emergent Resistance Through Three Years in Phase 3 HIV Clinical Trials
October
-
October 31, 2019
Gilead and Galapagos to Present New Data on Filgotinib at 2019 ACR/ARP Annual Meeting -
October 28, 2019
Gilead and Glympse Bio Announce Strategic Collaboration for Use of Biomarker Technology in NASH Clinical Development -
October 24, 2019
Gilead Sciences Announces Fourth Quarter 2019 Dividend -
October 24, 2019
Gilead Sciences Announces Third Quarter 2019 Financial Results -
October 15, 2019
Gilead Sciences Appoints Andrew Dickinson as Chief Financial Officer -
October 10, 2019
Gilead and Galapagos Announce Efficacy and Safety Results of Filgotinib Through 52 Weeks in FINCH 1 and FINCH 3 Studies in Rheumatoid Arthritis -
October 10, 2019
Gilead Sciences to Release Third Quarter 2019 Financial Results on Thursday, October 24, 2019 -
October 08, 2019
Gilead Sciences Submits New Drug Application for Filgotinib for the Treatment of Adults With Rheumatoid Arthritis in Japan -
October 07, 2019
Gilead Sciences Appoints Merdad Parsey, MD, PhD as Chief Medical Officer -
October 04, 2019
Gilead Presents New Data From the Company’s HIV Clinical Development Program and Latest Findings on the Impact of HIV Pre-exposure Prophylaxis (PrEP) at IDWeek 2019 -
October 03, 2019
U.S. Food and Drug Administration Approves Descovy® for HIV Pre-Exposure Prophylaxis (PrEP)
September
August
-
August 26, 2019
Gilead Sciences to Present at the Morgan Stanley Global Healthcare Conference on Tuesday, September 10 -
August 23, 2019
Gilead and Galapagos Complete Closing of Their Transformative Research and Development Collaboration -
August 15, 2019
European Medicines Agency Validates Marketing Application for Filgotinib for the Treatment of Rheumatoid Arthritis -
August 09, 2019
China National Medical Products Administration Approves Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) for Treatment of HIV-1 Infection -
August 07, 2019
Gilead Sciences Statement on U.S. Food and Drug Administration Advisory Committee’s Recommendation on Descovy for PrEP™
July
-
July 30, 2019
Gilead Sciences Announces Third Quarter 2019 Dividend -
July 30, 2019
Gilead Sciences Announces Second Quarter 2019 Financial Results -
July 23, 2019
Gilead Announces Latest Data in Ongoing HIV Cure Research Program -
July 23, 2019
Gilead Presents New Findings on Profile of Descovy® for Potential Use as HIV Pre-exposure Prophylaxis Compared With Truvada® -
July 22, 2019
Gilead Presents New Data on Biktarvy® for the Treatment of HIV in Women and in Virologically Suppressed Patients With Known Resistance -
July 22, 2019
Gilead Presents Proof-of-Concept Data for GS-6207, a First-in-Class Capsid Inhibitor, in People Living With HIV -
July 19, 2019
Gilead Sciences Licenses Respiratory and Herpes Antiviral Research Programs From Novartis -
July 18, 2019
Gilead to Present New Data on HIV Prevention, Treatment and Cure Research at IAS 2019 -
July 17, 2019
Gilead Sciences Announces Changes to Senior Leadership Team -
July 17, 2019
Gilead Sciences’ Chief Scientific Officer John McHutchison to Leave the Company -
July 16, 2019
Gilead Sciences to Release Second Quarter 2019 Financial Results on Tuesday, July 30, 2019 -
July 16, 2019
Kite Announces Plans to Bolster Industry-Leading Cell Therapy Manufacturing Capabilities With New Viral Vector Facility -
July 14, 2019
Gilead and Galapagos Enter Into Transformative Research and Development Collaboration -
July 11, 2019
Gilead Appoints Christi L. Shaw as Chief Executive Officer of Kite -
July 11, 2019
Gilead Sciences and Renown Institute for Health Innovation Announce Strategic Collaboration to Advance Understanding of Nonalcoholic Steatohepatitis (NASH) -
July 01, 2019
Gilead Announces Intent to Submit New Drug Application for Filgotinib to U.S. Food and Drug Administration This Year
June
-
June 26, 2019
Louisiana Launches Hepatitis C Innovative Payment Model With Asegua Therapeutics, Aiming to Eliminate the Disease -
June 24, 2019
Gilead and Carna Biosciences Announce Research and Development Collaboration to Develop Novel Immuno-Oncology Therapies -
June 19, 2019
Gilead and Nurix Establish Strategic Collaboration to Develop Novel Therapies for Cancer and Other Diseases -
June 03, 2019
Kite Announces New Yescarta® Data From ZUMA-1 -
June 01, 2019
Kite Announces End of Phase 1 ZUMA-3 Results for KTE-X19 in Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia
May
-
May 31, 2019
Kite and Humanigen Announce Clinical Collaboration to Evaluate Investigational Combination of Yescarta® (Axicabtagene Ciloleucel) with Lenzilumab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma -
May 29, 2019
Gilead and Galapagos to Present Latest Data on Filgotinib at the Annual European Congress of Rheumatology (EULAR 2019) -
May 29, 2019
Gilead Sciences Appoints Johanna Mercier as Chief Commercial Officer -
May 21, 2019
Gilead Sciences to Present at the Jefferies 2019 Global Healthcare Conference on Wednesday, June 5 -
May 15, 2019
Kite to Present New Data From Leading Cell Therapy Portfolio at ASCO 2019 -
May 09, 2019
Gilead Sciences to Provide Free Truvada for PrEP® to Support U.S. Initiative to End the HIV Epidemic -
May 08, 2019
Gilead Sciences and Goldfinch Bio Announce Strategic Collaboration to Develop Novel Therapies for Kidney Disease -
May 06, 2019
Gilead Sciences to Present at the Bank of America Merrill Lynch 2019 Health Care Conference on Tuesday, May 14 -
May 02, 2019
Gilead Sciences Announces Second Quarter 2019 Dividend -
May 02, 2019
Gilead Sciences Announces First Quarter 2019 Financial Results
April
-
April 30, 2019
Gilead Sciences’ Chief Financial Officer Robin Washington to Step Down in Early 2020 -
April 25, 2019
Gilead Announces Topline Data From Phase 3 STELLAR-3 Study of Selonsertib in Bridging Fibrosis (F3) Due to Nonalcoholic Steatohepatitis (NASH) -
April 24, 2019
Kite Announces Plans for New State-of-the-Art Facility to Expand Cell Therapy Production Capabilities -
April 18, 2019
Gilead Sciences to Release First Quarter 2019 Financial Results on Thursday, May 2, 2019 -
April 16, 2019
Gilead and insitro Announce Strategic Collaboration to Discover and Develop Novel Therapies for Nonalcoholic Steatohepatitis -
April 12, 2019
Gilead Sciences and Novo Nordisk Announce Intent to Initiate a Clinical Collaboration in NASH -
April 11, 2019
Gilead Presents New Data on Viral Hepatitis at the International Liver Congress™ 2019 -
April 11, 2019
Gilead Presents New Data in Nonalcoholic Steatohepatitis (NASH) at the International Liver Congress™ 2019 -
April 09, 2019
Gilead Announces New Grant Programs Supporting Investigator-Sponsored Research in Liver Diseases -
April 05, 2019
Gilead Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Once-Daily Descovy® for HIV Pre-Exposure Prophylaxis
March
-
March 28, 2019
Gilead and Galapagos Announce Filgotinib Meets Primary Endpoint in the Phase 3 FINCH 3 Study in Methotrexate-Naïve Rheumatoid Arthritis Patients -
March 28, 2019
Gilead and Galapagos Announce Filgotinib Meets Primary and Key Secondary Endpoints in the Phase 3 FINCH 1 Rheumatoid Arthritis Study -
March 28, 2019
Gilead and Galapagos Report Updated Safety Information for Filgotinib in Rheumatoid Arthritis (RA) -
March 28, 2019
Gilead Launches HepConnect Initiative to Reduce Hepatitis C Infections in Greater Appalachia -
March 27, 2019
Gilead to Present New Data From Multiple Liver Disease Research and Development Programs at The International Liver Congress™ 2019 -
March 26, 2019
Japan’s Ministry of Health, Labour and Welfare Approves Gilead’s Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) for Treatment of HIV-1 Infection -
March 07, 2019
Gilead Announces Data From Two Studies Supporting Further Development of GS-6207, a Novel, Investigational HIV-1 Capsid Inhibitor as a Component of Future Long-Acting HIV Therapies -
March 06, 2019
Gilead Presents Data on Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) in Virologically Suppressed Adults, Including Those With Pre-Existing NRTI Resistance -
March 06, 2019
Gilead Presents New Data on Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) and TAF-Based Regimens for the Treatment of HIV-1 in Children, Older Adults and Women -
March 06, 2019
Gilead Announces Data Demonstrating Non-Inferiority of Once-Daily Descovy® vs. Once-Daily Truvada® for Prevention of HIV Infection -
March 05, 2019
Gilead Announces Senior Management Change -
March 05, 2019
Gilead Sciences to Present at the Barclays Global Healthcare Conference on Tuesday, March 12
February
-
February 26, 2019
Gilead Sciences Launches Age Positively Initiative to Address Unique Challenges of Aging Population Living with HIV -
February 11, 2019
Gilead Announces Topline Data From Phase 3 STELLAR-4 Study of Selonsertib in Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH) -
February 04, 2019
Gilead Sciences Announces 11 Percent Increase in First Quarter 2019 Dividend -
February 04, 2019
Gilead Sciences Announces Fourth Quarter and Full Year 2018 Financial Results
January
-
January 22, 2019
Gilead Sciences to Release Fourth Quarter and Full Year 2018 Financial Results on Monday, February 4, 2019 -
January 08, 2019
Japan’s Ministry of Health, Labour and Welfare Approves Gilead’s Epclusa® (Sofosbuvir/Velpatasvir) -
January 06, 2019
Gilead Sciences and Yuhan Corporation Announce Collaboration and License Agreement to Develop Novel Investigational Treatments for Advanced Fibrosis Due to Nonalcoholic Steatohepatitis -
January 02, 2019
Gilead Sciences to Present at the 37th Annual J.P. Morgan Healthcare Conference on Monday, January 7
Filter By Year